Tyrosine kinase inhibitors (TKIs) have revolutionized CML treatment, offering more effective and better-tolerated options than previous therapies. Second- and third-generation TKIs address resistance ...

Chronic myeloid leukemia highlights from ASH 2025 include data on nilotinib vs imatinib, asciminib in second line, somatic ...

Nilotinib (Tasigna®) is a highly potent and selective inhibitor of breakpoint cluster region (BCR)–V-abl Abelson murine leukemia viral oncogene homolog 1 (ABL1), which was rationally designed based on ...

Status of Therapy for Chronic Myeloid Leukemia: Review of Drug Development Chronic myeloid leukemia treatment is relatively effective, but some problems have begun to emerge. Learn what the problems ...

Researchers recently calculated the estimated savings over a 30-year period with regard to CML patients who attempt to get off their TKI therapy. In what they referred to as a 'conservative' estimate, ...

Arsenic and old ideas once used to treat a deadly cancer are being overhauled by enormous strides in new treatments, turning ...